Consensus Guidelines for the Definition of Time-to-Event End Points in Image-guided Tumor AblationĪ panel of 62 specialists published a report in Radiology, last September 28, aiming at increasing research on image-guided procedures and standardizing patient care in this IO technique, which has seen a rise in adoption, but still lacks established guidelines and standards that are widely adopted and can ensure consistency of outcomes throughout different practices and even between different physicians within the same institution. Overall, IO enables less pain, fewer side effects, and shorter recovery times (sometimes even in an outpatient ambulatory setting). Interventional Oncology thus presents itself as an optimal solution for several different treatment pathways: image guidance can allow for easier tumor access, IO therapies can be used as palliative and/or to shrink tumors and allow for surgical resection (in cases where it was not possible before), and co-treatment is possible, i.e., it becomes possible to combine IO techniques and any other technique from the other cancer care pillars. Some patients may also be too weak to undergo open surgery. While the surgical resection of tumors usually offers the best long-term therapeutical solution, it is often not possible due to the size, number or location of the tumor(s), not to mention it is always substantially impactful and subject to more complications and a longer recovery time. With the paradigm shift towards minimally invasive approaches, IO is taking a more prominent role in the oncology realm, as it is less invasive than traditional methods and approaches, and interventional radiologists often find creative and innovative ways to treat lesions while minimizing the impact of the intervention. It relies primarily on embolization or ablation to destroy tumors. Interventional oncology is a subspecialty of interventional radiology that focuses on image-guided procedures to deliver endovascular (embolization) or percutaneous (ablation) treatment to identified cancers. Interventional Oncology (IO) is now considered the fourth pillar of modern cancer care. Although immunotherapy specialists devised ingenious ways to use the patients’ own immune system to better fight cancer, this approach is set to replace conventional chemotherapy, given its clear advantages. These pillars address tumors directly, removing or destroying lesions. Until the late 90s, modern cancer care consisted of three pillars of treatment: surgery (through tumor resection), radiation therapy, and chemotherapy. The 3rd application would be early in the grain fill or fruit/vegetable sizing stage.Interventional Oncology, the 4th pillar of modern cancer care Second application is usually just before flowering, or just before the onset of the reproductive stage of the crop. Plants need to be just past the seedling stage - about 25% coverage of the ground before the first application. per acre as a foliar application, 2-3 times per growing season recommended for row crops and forages. in the seed furrow as a starter with constant agitation and/or 2-4 lbs. The natural pH of 3.7 enables Micromate to be safely used in all types of agriculture, horticulture and home uses.ġ-2 lbs. Micromate is totally organic, non-toxic and safe to handle. When in liquid form, a total humic/fulvic acid analysis of 24% exceeds any known liquid product on the market. Micromate uses the advantage of the tremendous surface area to more readily improve your plants and soil. Micromate is the result of a revolutionary new micronizing technology and can be suspended in a liquid to deliver the maximum possible concentration of humic/fulvic acids, plus the important humin fraction, to your plants and soil in a liquid form (shipped as a dry concentrate). Micronized Humate Product for Liquid SuspensionĪll Natural Soil Conditioner Net Weight - 30 lbs.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |